Ifosfamide

• CAT Number: A000302
• CAS Number: 3778-73-2
• Molecular Formula: C7H15Cl2N2O2P
• Molecular Weight: 261.1
• Purity: ≥95%
• Target: DNA Synthesis
• Solubility: >13.1mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)
• InChIKey: HOMGKSMUEGBAAB-UHFFFAOYSA-N
• SMILES: C1CN(P(=O)(OC1)NCCCl)CCCl

Ifosfamide is a synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication. This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Reference

1: Russo C, Lavorgna M, Česen M, Kosjek T, Heath E, Isidori M. Evaluation of
acute and chronic ecotoxicity of cyclophosphamide, ifosfamide, their
metabolites/transformation products and UV treated samples. Environ Pollut. 2017
Oct 27;233:356-363. doi: 10.1016/j.envpol.2017.10.066. [Epub ahead of print]
PubMed PMID: 29096309.

2: Sannu A, Radha R, Mathews A, Padmakumari Mony R, Prahladan A, James FV.
Ifosfamide-Induced Malignancy of Ureter and Bladder. Cureus. 2017 Aug
22;9(8):e1594. doi: 10.7759/cureus.1594. PubMed PMID: 29062626; PubMed Central
PMCID: PMC5650260.

3: Snyder M, Gangadhara S, Brohl AS, Ludlow S, Nanjappa S. Serotonin Syndrome
Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue. Cancer
Control. 2017 Oct-Dec;24(5):1073274817729070. doi: 10.1177/1073274817729070.
PubMed PMID: 28975823.

4: Colia V, Fumagalli E, Provenzano S, Bertulli R, Stacchiotti S, Morosi C,
Collini P, Gronchi A, Casali PG, Sanfilippo R. High-Dose Ifosfamide Chemotherapy
in a Series of Patients Affected by Myxoid Liposarcoma. Sarcoma.
2017;2017:3739159. doi: 10.1155/2017/3739159. Epub 2017 Aug 30. PubMed PMID:
28947876; PubMed Central PMCID: PMC5602616.

5: Seno N, Fukushima T, Gomi D, Kobayashi T, Sekiguchi N, Matsushita H, Ozawa T,
Tsukahara Y, Mamiya K, Koizumi T, Sano K. Successful treatment with doxorubicin
and ifosfamide for mediastinal malignant peripheral nerve sheath tumor with loss
of H3K27me3 expression. Thorac Cancer. 2017 Nov;8(6):720-723. doi:
10.1111/1759-7714.12498. Epub 2017 Sep 6. PubMed PMID: 28876532.

6: Colia V, Fiore M, Provenzano S, Fumagalli E, Bertulli R, Morosi C, Tos APD,
Barisella M, Gronchi A, Casali PG, Sanfilippo R. Activity of anthracycline- and
ifosfamide-based chemotherapy in a series of patients affected by advanced
myxofibrosarcoma. Clin Sarcoma Res. 2017 Aug 22;7:16. doi:
10.1186/s13569-017-0082-6. eCollection 2017. PubMed PMID: 28852467; PubMed
Central PMCID: PMC5568720.

7: Muzaffar M, Atluri PM, Liles D. Acute Inflammatory Demyelinating
Polyradiculoneuropathy Secondary to Ifosfamide. Am J Ther. 2017 Aug 8. doi:
10.1097/MJT.0000000000000594. [Epub ahead of print] PubMed PMID: 28816726.

8: Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S,
Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR,
Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of
panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in
relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 2017 Aug 9:1-8.
doi: 10.1080/10428194.2017.1359741. [Epub ahead of print] PubMed PMID: 28792260.

9: Bun S, Yonemori K, Akagi T, Noguchi E, Shimoi T, Shimomura A, Yunokawa M,
Shimizu C, Fujiwara Y, Makino Y, Hayashi Y, Tamura K. Feasibility of olanzapine,
multi acting receptor targeted antipsychotic agent, for the prevention of emesis
caused by continuous cisplatin- or ifosfamide-based chemotherapy. Invest New
Drugs. 2017 Jul 21. doi: 10.1007/s10637-017-0487-3. [Epub ahead of print] PubMed
PMID: 28733700.

10: Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D,
Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin
RS. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing
Sarcoma in Adults. Oncologist. 2017 Oct;22(10):1271-1277. doi:
10.1634/theoncologist.2016-0464. Epub 2017 Jul 14. PubMed PMID: 28710342; PubMed
Central PMCID: PMC5634776.